Regeneron Pharmaceuticals (REGN) Expected to Announce Quarterly Earnings on Wednesday

Regeneron Pharmaceuticals (NASDAQ:REGN) is expected to release its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect Regeneron Pharmaceuticals to post earnings of $9.10 per share and revenue of $3.4479 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 8:30 AM ET.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $12.07 EPS. On average, analysts expect Regeneron Pharmaceuticals to post $35 EPS for the current fiscal year and $41 EPS for the next fiscal year.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $747.36 on Wednesday. The stock’s 50-day moving average price is $764.87 and its two-hundred day moving average price is $729.56. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The company has a market cap of $79.01 billion, a PE ratio of 17.98, a PEG ratio of 1.67 and a beta of 0.40. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $821.11.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Friday, February 20th. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.05%.

Insider Activity

In other news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,774 shares of company stock worth $2,942,738 in the last 90 days. Company insiders own 7.02% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Brighton Jones LLC increased its stake in shares of Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the last quarter. DV Equities LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $110,000. Aster Capital Management DIFC Ltd increased its stake in shares of Regeneron Pharmaceuticals by 136.5% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 272 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 157 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in shares of Regeneron Pharmaceuticals by 70.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 278 shares of the biopharmaceutical company’s stock worth $215,000 after purchasing an additional 115 shares during the last quarter. Finally, Zions Bancorporation National Association UT increased its stake in shares of Regeneron Pharmaceuticals by 342.2% during the 4th quarter. Zions Bancorporation National Association UT now owns 283 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 219 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on REGN. JPMorgan Chase & Co. boosted their price objective on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Oppenheimer reiterated an “outperform” rating and issued a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Finally, Royal Bank Of Canada upped their target price on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $811.96.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Cemdisiran Phase 3 success — The NIMBLE Phase 3 trial met primary and key secondary endpoints at week 24 for generalized myasthenia gravis (gMG); data were published in The Lancet and presented at AAN, Regeneron submitted a U.S. regulatory application and says cemdisiran could be the first siRNA approved for gMG, which would add a novel, potentially high-value asset to the pipeline. Cemdisiran Phase 3 Trial
• Positive Sentiment: Label expansion and radiopharmaceutical move — EU approval broadened Dupixent’s pediatric label (chronic spontaneous urticaria, ages 2–11), supporting incremental revenue upside; Regeneron also announced a collaboration with Telix to co-develop next‑generation radiopharmaceuticals for solid tumors, signaling diversification beyond biologics. Both items expand addressable markets. Dupixent & Telix Collaboration
• Neutral Sentiment: Investor visibility — Management will webcast presentations at BofA Health Care (May 12) and Goldman Sachs Global Healthcare (June 8), which could provide updated commercial and pipeline commentary but are unlikely by themselves to move the stock dramatically. Investor Conference Presentations
• Neutral Sentiment: Sector narrative — A recent Motley Fool piece flagged biotech as a long‑term growth category for patient investors; this helps the overall investor backdrop for large-cap innovators like Regeneron but is a broad-market view rather than company‑specific news. Fool: Biotech Picks
• Negative Sentiment: Regulatory & execution risks remain — Cemdisiran still needs regulatory approval and successful launch execution; the Telix radiopharma program will require clinical development and commercialization investment, and any delays or safety/regulatory setbacks could weaken the positive readthroughs. These risks help explain why the stock can drift lower even after favorable headlines. Cemdisiran Trial (Risks)

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.